Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases

Eike C. Buss, MD, Julian Topaly, MD, Hans H. Kreipe, MD, Stefan Fruehauf, MD, Anthony D. Ho, MD

Blood (2011) 118 (21): 4514.

https://doi.org/10.1182/blood.V118.21.4514.4514

Published: 2011

Journal Articles

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Leopold Sellner, MD, Marlon R Veldwijk, PhD, Jürgen A. Kleinschmidt, PhD, Stephanie Laufs, PhD, Julian Topaly, MD, W. Jens Zeller, MD, Frederik Wenz, MD, Stefan Fruehauf, MD

Blood (2009) 114 (22): 4506.

https://doi.org/10.1182/blood.V114.22.4506.4506

Published: 2009

Journal Articles

Efficient Gene Transfer into Human CD34 + Peripheral Blood Progenitor Cells Using Pseudotyped Recombinant Adeno-Associated Viral Vectors

Leopold Sellner, Marlon Veldwijk, PhD, Marius Stiefelhagen, Jurgen A. Kleinschmidt, PhD, Stephanie Laufs, PhD, Julian Topaly, MD, W. Jens Zeller, MD, Frederik Wenz, MD, Stefan Fruehauf, MD

Blood (2008) 112 (11): 4627.

https://doi.org/10.1182/blood.V112.11.4627.4627

Published: 2008

Journal Articles

Novel Efficient Primary Human Peripheral Blood Progenitor Cell-Targeted Recombinant Adeno-Associated Viral Vectors.

Marlon R. Veldwijk, Ph.D., Leopold Sellner, Marius Stiefelhagen, Jürgen A. Kleinschmidt, Ph.D., Stephanie Laufs, Ph.D., Julian Topaly, M.D., Frederik Wenz, M.D., W. Jens Zeller, M.D., Stefan Fruehauf, MD

Blood (2007) 110 (11): 5144.

https://doi.org/10.1182/blood.V110.11.5144.5144

Published: 2007

Journal Articles

Synergistic Activity of Nilotinib and Established Chemotherapeutic Agents in Imatinib-Sensitive and -Resistant BCR-ABL -Positive Leukemia Cells.

Aleksandar Radujkovic, Julian Topaly, Anthony D. Ho, W.J. Zeller, Stefan Fruehauf

Blood (2006) 108 (11): 4778.

https://doi.org/10.1182/blood.V108.11.4778.4778

Published: 2006

Journal Articles

Treatment of Imatinib-Sensitive and -Resistant Chronic Myelogenous Leukemia Cells with a Combination of Imatinib and Farnesyltransferase Inhibitors.

Aleksandar Radujkovic, Julian Topaly, MD, W. Jens Zeller, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD

Blood (2005) 106 (11): 4881.

https://doi.org/10.1182/blood.V106.11.4881.4881

Published: 2005

Journal Articles

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Tanja Lahaye, MD, Oliver G. Ottmann, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Ulrike Haus, Rudiger Hehlmann, MD, Anthony D. Ho, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1105.

https://doi.org/10.1182/blood.V106.11.1105.1105

Published: 2005

Journal Articles

Highly Efficient Peripheral Blood Progenitor Cell Mobilization in Myeloma Patients by Single-Dose Application of 12 mg Pegylated G-CSF.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2005) 106 (11): 5264.

https://doi.org/10.1182/blood.V106.11.5264.5264

Published: 2005

Journal Articles

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Stefan Fruehauf, MD, Timon Seeger, Julian Topaly, MD, Doris Herrmann, PhD, Falk Dillmann, Per Humpert, MD, Gary Calandra, MD, PhD, Stephanie Laufs, PhD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2005) 106 (11): 1961.

https://doi.org/10.1182/blood.V106.11.1961.1961

Published: 2005

Journal Articles

Myeloablative Conditioning in Myelofibrosis using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation with High Doses of CD34+ Cells Results in Hematologic Responses - Follow-Up of Three Patients.

Stefan Fruehauf, Eike C. Buss, Julian Topaly, Hans H. Kreipe, Anthony D. Ho

Blood (2004) 104 (11): 5220.

https://doi.org/10.1182/blood.V104.11.5220.5220

Published: 2004

Journal Articles

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Harald Gschaidmeier, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2004) 104 (11): 2929.

https://doi.org/10.1182/blood.V104.11.2929.2929

Published: 2004

Journal Articles

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Aleksandar Radujkovic, Moritz Schad, Julian Topaly, MD, Stephanie Laufs, PhD, Anna Jauch, MD, Beate Schultheis, MD, Junia V. Melo, MD, Anthony D. Ho, MD, Stefan Fruehauf, MD, W. Jens Zeller, MD

Blood (2004) 104 (11): 2094.

https://doi.org/10.1182/blood.V104.11.2094.2094

Published: 2004

Journal Articles

Sufficient Mobilization of Peripheral Blood Stem Cells by Single Dose Application of Pegylated G-CSF in Patients with Multiple Myeloma, Interim Analysis of a Phase II Study.

Stefan Fruehauf, Seeger Timon, Eike C. Buss, Julian Topaly, Anthony D. Ho, Hartmut Goldschmidt

Blood (2004) 104 (11): 946.

https://doi.org/10.1182/blood.V104.11.946.946

Published: 2004

NARROW

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Efficient Gene Transfer into Human CD34 + Peripheral Blood Progenitor Cells Using Pseudotyped Recombinant Adeno-Associated Viral Vectors

Novel Efficient Primary Human Peripheral Blood Progenitor Cell-Targeted Recombinant Adeno-Associated Viral Vectors.

Synergistic Activity of Nilotinib and Established Chemotherapeutic Agents in Imatinib-Sensitive and -Resistant BCR-ABL -Positive Leukemia Cells.

Treatment of Imatinib-Sensitive and -Resistant Chronic Myelogenous Leukemia Cells with a Combination of Imatinib and Farnesyltransferase Inhibitors.

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Highly Efficient Peripheral Blood Progenitor Cell Mobilization in Myeloma Patients by Single-Dose Application of 12 mg Pegylated G-CSF.

The CXCR4-Antagonist AMD3100 Augments the Number of Mobilized Peripheral Blood Progenitor Cells (PBPC) When Added to a G-CSF Standard Mobilization Regime and AMD3100-Mobilized PBPC Result in Rapid Hematopoietic Reconstitution after Autologous Transplantation.

Myeloablative Conditioning in Myelofibrosis using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation with High Doses of CD34+ Cells Results in Hematologic Responses - Follow-Up of Three Patients.

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Synergism between 17-AAG and Imatinib in Imatinib-Resistant CML Cells: Inhibition of P-Glycoprotein by 17-AAG as a New Mechanism of Increasing Imatinib Activity.

Sufficient Mobilization of Peripheral Blood Stem Cells by Single Dose Application of Pegylated G-CSF in Patients with Multiple Myeloma, Interim Analysis of a Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only